Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine

• Main Authors: Aliper, A. (Author), de Magalhães, J.P (Author), Izumchenko, E. (Author), Leung, G.H.D (Author), Leung, H.W (Author), Liu, B.H.M (Author), Long, X. (Author), Moskalev, A. (Author), Ozerov, I.V (Author), Pun, F.W (Author), Ren, F. (Author), Wang, J. (Author), Zhavoronkov, A. (Author)
• Format: Article
• Language: English
• Published: NLM (Medline) 2022
• Subjects: artificial intelligence; Artificial Intelligence; deep learning; drug development; drug discovery; Drug Discovery; drug repositioning; Drug Repositioning; multi-omics; procedures; protein; Proteins; target identification
• Online Access: View Fulltext in Publisher
• Physical Description: 32
• ISBN: 19454589 (ISSN)
• DOI: 10.18632/aging.203960

Aging biology is a promising and burgeoning research area that can yield dual-purpose pathways and protein targets that may impact multiple diseases, while retarding or possibly even reversing age-associated processes. One widely used approach to classify a multiplicity of mechanisms driving the aging process is the hallmarks of aging. In addition to the classic nine hallmarks of aging, processes such as extracellular matrix stiffness, chronic inflammation and activation of retrotransposons are also often considered, given their strong association with aging. In this study, we used a variety of target identification and prioritization techniques offered by the AI-powered PandaOmics platform, to propose a list of promising novel aging-associated targets that may be used for drug discovery. We also propose a list of more classical targets that may be used for drug repurposing within each hallmark of aging. Most of the top targets generated by this comprehensive analysis play a role in inflammation and extracellular matrix stiffness, highlighting the relevance of these processes as therapeutic targets in aging and age-related diseases. Overall, our study reveals both high confidence and novel targets associated with multiple hallmarks of aging and demonstrates application of the PandaOmics platform to target discovery across multiple disease areas.